LakeShore Biopharma Sees FY25 Revenues To Be Between RMB 665 Million - RMB 700 Million, Indicating Growth Of 16%-22% YoY
LakeShore Biopharma Sees FY25 Revenues To Be Between RMB 665 Million - RMB 700 Million, Indicating Growth Of 16%-22% YoY
FY2025 Guidance Update
2025財年指引更新
For the full FY2025, the Company expects total revenues to be between RMB 665 million and RMB 700 million, indicating a growth of 16% to 22% year-over-year. The Company also projects Adjusted EBITDA to range between RMB 76 million and RMB 89 million. These projections reflect the Company's positive outlook for the current fiscal year, which would establish significant foundation for fiscal year 2026.
對於整個2025財年，公司預計總收入將在66500萬令吉到70000萬令吉之間，同比增長率爲16%到22%。公司還預計調整後的EBITDA區間爲7600萬令吉到8900萬令吉。這些預測反映了公司對當前財政年度的積極展望，爲2026財年奠定了重要基礎。
The above outlook is based on information available as of the date of this press release and reflects the Company's current and preliminary views regarding its business situation and market conditions, which are subject to change.
上述展望基於截至本新聞稿日期可獲得的信息，反映了公司對其業務狀況和市場條件的當前和初步看法，這些情況可能會發生變化。
| [1] Adjusted net income (loss) is a non-GAAP financial measure, which is defined as net income (loss) excluding share-based compensation expenses and loss on disposal of property, plant and equipment. See "Use of Non-GAAP Financial Measures" below. |
| [2] EBITDA is a non-GAAP financial measure, which is defined as net income (loss) before income tax expense (benefit), financial expenses - net and depreciation and amortization. See "Use of Non-GAAP Financial Measures" below. |
| [3] Adjusted EBITDA is a non-GAAP financial measure, which is defined as net income/(loss) before income tax expense (benefit), financial expenses - net, and depreciation and amortization ("EBITDA") adjusted to exclude share-based compensation expenses, late fees related to social security insurance, other income (expense) - net, fair value changes of warrant liability, and government grants. See "Use of Non-GAAP Financial Measures" below. |
| [1] 調整後的凈利潤（損失）是一項非GAAP財務指標，定義爲排除基於股份的薪酬費用和處置物業、廠房和設備的損失後的凈利潤（損失）。請參見下文"非GAAP財務指標的使用"。 |
| [2] EBITDA是一項非GAAP財務指標，定義爲在所得稅費用（收益）、財務費用-淨額及折舊和攤銷之前的凈利潤（損失）。請參見下文"非GAAP財務指標的使用"。 |
| [3] 調整後的EBITDA是一項非GAAP財務指標，定義爲在所得稅費用（收益）、財務費用-淨額及折舊和攤銷（"EBITDA"）之前的凈利潤/（損失），並調整排除基於股份的薪酬費用、與社會保險相關的逾期費用、其他收入（費用）-淨額、認股權證負債的公允價值變動以及政府補助。請參見下文"非GAAP財務指標的使用"。 |
譯文內容由第三人軟體翻譯。